NCT03758950View on ClinicalTrials.gov

Inhaled Mometasone to Promote Reduction in Vasoocclusive Events 2

PHASE2CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

November 29, 2018

Primary Completion Date

May 31, 2023

Study Completion Date

May 31, 2023

Conditions
Sickle Cell Disease
Interventions
DRUG

Placebo

Once daily inhaled placebo for 48 weeks

DRUG

Mometasone

Inhaled Mometasone for 48 weeks (with 4-week washout at study completion)

Trial Locations (2)

10025

Mount Sinai St Luke's, New York

10029

Icahn School of Medicine at Mount Sinai, New York

All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

Jeffrey Glassberg

OTHER

NCT03758950 - Inhaled Mometasone to Promote Reduction in Vasoocclusive Events 2 | Biotech Hunter | Biotech Hunter